L'EQ Score indique l'activité et l'attractivité de l'entreprise sur la plateforme : complétude du profil, actualités, likes, follows, appartenance à un ou plusieurs labels ou communautés, nombre de membres de son réseau, etc.
HCS PHARMA développe et commercialise des produits de culture cellulaire 3D basés sur sa technologie disruptive, exclusive et propriétaire BIOMIMESYS, hydrosquelette qui permet de reproduire la matrice extracellulaire de façon organe-spécifique.
Lille, Hauts-de-France, France
Envoyer un message
In 2020, HCS Pharma has been selected to be part of the InvestHorizon coaching program. In this coaching program, 500 investors challenged over 1,000 selected tech entrepreneurs over multiple sessions to level up their investment and growth.
During this coaching program, we have participated in several events to be challanged by experts and investors. We are proud to received a new label during this coaching program: Top Health Companies - InvestHorizon Pitching Forum and finally, we are proud to have been selected to be part of the Tech Tour Future 21 event this year.
During this event, 48 starp-up from health has been selected (4 deeptech, 29 digital health, 7 Medtech and 8 pharma & biotech). The presence of a majority of startups in digital health reflects the majority of investments made by European investors.
This event was amazing. I was able to pitch in front of 500 investors: https://hcs-pharma.com/techtour-2021-presention-hcs-pharma/. I had more than 15 BtoB meetings.
3D cell culture systems have recently as promising tools for reproducing the cellular environment and the organization of tissues/organs, where cells are connected to each other and to the surrounding extracellular matrix (ECM). Join us for this webinar to know more about BIOMIMESYS® technology, our 3D cell culture system designed for the physiologically-relevant culture of liver, brain, adipose tissue, and cancer cells in dedicated BIOMIMESYS® hydroscaffolds. Each matrix is characterized by its specific composition and stiffness, to be in accordance with in vivo conditions.
As you may know, in HCS Pharma we strongly believe that the critical point of the human health evolution in next years is the in vitro 3D cell culture, especially for complex diseases like cancer . It’s why we work hard on our exclusive BIOMIMESYS® technology. As experts in HCS and cell imaging, we must master all the process : 3D biological models, 3D cell culture, volumetric pictures acquisition, 3D reconstruction and segmentation of cells and ECM compounds, 3D parameters extraction and, of course, biological interpretations. As explained in our VisuAI R&D project, the 3D reconstruction and segmentation step is not simple.
A PhD student begun to work on the subject at the end of 2019 with the help with great partners (ISEN engineering school, BioMEMS team (IEMN) and TISBIO team of Université de Lille). We get now very interesting results, soon published. Briefly, the first step was to use Machine Learning algorithms and compare them altogether and with humans expertise. One specific difficulty was also to find the right key comparators, as segmentation is not perfect, even made by humans.
A scientific article is about to be published.
Next step is to work on Deep Learning algorithms  to overcome the Z-stack problem and the multi-dataset problem and working on a robust architecture that take into consideration the different layers properties.
HCS Pharma was invited to pitch in front of 45+ Expert Jury Members last week for the online event "InvestHorizon Pitching eForum Health 2.0". It was a real pleasure for our CEO, Nathalie Maubon, to share company's vision on future drugs developement. Find below this pitch and, of course, feel free to directly contact Nathalie for more information.
Among 370 applications from 54 countries, I am proud to be selected with 9 other start-ups for Female Founder Challenge organized by Vivatechnology & 50inTech. We are to women frmn France.
“In Europe, 92% of the funds were invested in startups founded by men. The tech sector needs to be more mixed and inclusive, ”says Julie Ranty, director of VivaTech. Thus VivaTech created The Female Founder Challenge with 50inTech last year. This challenge aims to accelerate the financing of women-led start-ups and involve venture capital funds at a greater parity in financing.
After a coaching session, we have done a 3min pitch “live” on June 18 in front of more than 50 investors around the world. The challenge is great and we are proud to be part of it.
You want to know more on this Female Founder Challenge 2020, follow the link
- for the complete sessions : https://www.youtube.com/watch?v=n0v_uKlhGzc
- for the 3min ptch of HCS Pharma: https://www.youtube.com/watch?v=n0v_uKlhGzc&t=1395s
Débute le 08/2014
HCS Pharma founded by Nathalie MAUBON as a CRO
fund raising with FINOVAM & NFA: seed
New site with 250 m² of space with: - 2 cell culture labs - 1 automation lab with 1 robotic platform